Oxidative stress, metalloproteinase and LDH in children with intractable and non-intractable epilepsy as reflected in salivary analysis

Epilepsy Research

Volumn 108, Issue 1, 2014, Pages 117-124

  Shahar, Eli ^a,c   Attias, Uri ^a   Savulescu, Dana ^b,c   Genizin, Jacob ^a   Gavish, Moshe ^b,c   Nagler, Rafael ^b,c  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b Molecular Pharmacology Department and Oral Biochemistry Laboratory   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Epilepsy; Intractable epilepsy; LDH; Metalloproteinases; Oxidative stress; Saliva

Indexed keywords

CARBONYL DERIVATIVE; GELATINASE A; GELATINASE B; LACTATE DEHYDROGENASE; METALLOPROTEINASE; PEROXIDASE; STROMELYSIN; SUPEROXIDE DISMUTASE;

ARTICLE; CHILD; CHILD HEALTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; FOLLOW UP; HUMAN; INTRACTABLE EPILEPSY; MALE; NON INVASIVE MEASUREMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; SALIVA ANALYSIS; SALIVA LEVEL; SENSITIVITY AND SPECIFICITY;

EPILEPSY; INTRACTABLE EPILEPSY; LDH; METALLOPROTEINASES; OXIDATIVE STRESS; SALIVA;

BIOLOGICAL MARKERS; CHILD; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; OXIDATIVE STRESS; SALIVARY PROTEINS AND PEPTIDES;

EID: 84890787515     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.10.003     Document Type: Article

References (43)

1. Amantea D., Nappi G., Bernardi G., Bagetta G., Corasaniti M.T. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 2009, 276(1):13-26.
2. Attilakos A., Voudris K.A., Garoufi A., Mastroyianni S., Dimou S., Prassouli A., Katsarou E. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study. Eur. J. Paediatr. Neurol. 2006, 10(5-6):237-240.
3. Avivi I., Avraham S., Koren-Michowitz M., Zuckerman T., Aviv A., Ofran Y., Nagler A., Rowe J.M., Nagler R.M. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT. Bone Marrow Transplant. 2009, 43(10):801-806.
4. Bruce A.J., Baudry M. Oxygen free radicals in rat limbic structures after kainate-induced seizures. Free Radic. Biol. Med. 1995, 18(6):993-1002.
5. Chang S.J., Yu B.C. Mitochondrial matters of the brain: mitochondrial dysfunction and oxidative status in epilepsy. J. Bioenerg. Biomembr. 2010, 42(6):457-459.
6. Costello D.J., Delanty N. Oxidative injury in epilepsy: potential for antioxidant therapy?. Expert Rev. Neurother. 2004, 4(3):541-553.
7. Devi P.U., Manocha A., Vohora D. Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers. Expert Opin. Pharmacother. 2008, 9(18):3169-3177.
8. El-Abhar H.S., El Gawad H.M. Modulation of cortical nitric oxide synthase, glutamate, and redox state by nifedipine and taurine in PTZ-kindled mice. Epilepsia 2003, 44(3):276-281.
9. Eraković V., Zupan G., Varljen J., Simonić A. Pentylenetetrazol-induced seizures and kindling: changes in free fatty acids, superoxide dismutase, and glutathione peroxidase activity. Neurochem. Int. 2003, 42(2):173-178.
10. Folbergrová J., Kunz W.S. Mitochondrial dysfunction in epilepsy. Mitochondrion. 2012, 12(1):35-40.
11. Fossati P., Prencipe L., Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin. Chem. 1980, 26(2):227-231.
12. Frantseva M.V., Perez Velazquez J.L., Tsoraklidis G., Mendonca A.J., Adamchik Y., Mills L.R., Carlen P.L., Burnham M.W. Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. Neuroscience 2000, 97(3):431-435.
13. Hamada T., Duarte S., Tsuchihashi S., Busuttil R.W., Coito A.J. Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am. J. Pathol. 2009, 174(6):2265-2277.
14. Hamed S.A., Abdellah M.M., El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J. Pharmacol. Sci. 2004, 96(4):465-473.
15. Kawakami Y., Monobe M., Kuwanara K., Fujita T., Maeda M., Fujino O., Fukunaga Y. A comparative study of nitric oxide, glutathione, and glutathione peroxidase activities in cerebrospinal fluid from children with convulsive diseases/children with aseptic meningitis. Brain Dev. 2006, 28:243-246.
16. Konopacki F.A., Rylski M., Wilczek E., Amborska R., Detka D., Kaczmarek L., Wilczynski G.M. Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA. Neuroscience 2007, 150(1):31-39.
17. Landmesser U., Wollert K.C., Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc. Res. 2009, 81(3):519-527.
18. Lee C.Z., Xue Z., Hao Q., Yang G.Y., Young W.L. Nitric oxide in vascular endothelial growth factor-induced focal angiogenesis and matrix metalloproteinase-9 activity in the mouse brain. Stroke 2009, 40(8):2879-2881.
19. Lorenzo Fernández P. Stress and neurodegeneration: pharmacologic strategies. R. Acad. Nac. Med. (Madr.) 1999, 116(2):417-430.
20. Luckman S.P., Gilhus N.E., Romi F. Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls. Autoimmune Dis. 2011, 2011:151258. (Epub 2011 Aug 1).
21. MacGregor D.G., Higgins M.J., Jones P.A., Maxwell W.L., Watson M.W., Graham D.I., Stone T.W. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. Brain Res. 1996, 727(1-2):133-144.
22. Moore S., Calder K.A.C., Miller N.J., Rice-Evans C.A. Antioxidant activity of saliva and periodontal disease. Free Radic. Res. 1994, 21(6):417-425.
23. Nagler R.M., Lischinsky S., Diamond E., Klein I., Reznick A.Z. New insights into salivary lactate dehydrogenase of human subjects. J. Lab. Clin. Med. 2001, 137(5):363-369.
24. Nagler R.M., Hershkovich O., Lischinsky S., Diamond E., Reznick A.Z. Saliva analysis in the clinical setting: revisiting an underused diagnostic tool. J. Investig. Med. 2002, 50(3):214-225.
25. Nagler R.M., Klein I., Zarzhevsky N., Drigues N., Reznick A.Z. Characterization of the differentiated antioxidant profile of human saliva. Free Radic. Biol. Med. 2002, 32(3):268-277.
26. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008, 99(8):1501-1506.
27. Patel M.N. Oxidative stress, mitochondrial dysfunction, and epilepsy. Free Radic. Res. 2002, 36(11):1139-1146.
28. Pruitt K.M., Kamau D.N., Miller K., Månsson-Rahemtulla B., Rahemtulla F. Quantitative, standardized assays for determining the concentrations of bovine lactoperoxidase, human salivary peroxidase, and human myeloperoxidase. Anal. Biochem. 1990, 191(2):278-286.
29. Pun P.B., Lu J., Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic. Res. 2009, 43(4):348-364.
30. Raffo E., Koning E., Nehlig A. Postnatal maturation of cytochrome oxidase and lactate dehydrogenase activity and age-dependent consequences of lithium-pilocarpine status epilepticus in the rat: a regional histoenzymology study. Pediatr. Res. 2004, 56(4):647-655.
31. Reed D.J., Pascoe G.A., Thomas C.E. Extracellular calcium effects on cell viability and thiol homeostasis. Environ. Health Perspect. 1990, 84:113-120.
32. Romi F., Helgeland G., Gilhus N.E. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur. Neurol. 2012, 67(2):121-128.
33. Shpitzer T., Bahar G., Feinmesser R., Nagler R.M. A comprehensive salivary analysis for oral cancer diagnosis. J. Cancer Res. Clin. Oncol. 2007, 133(9):613-617.
34. Sobaniec H., Sobaniec W., Sendrowski K., Sobaniec S., Pietruska M. Antioxidant activity of blood serum and saliva in patients with periodontal disease treated due to epilepsy. Adv. Med. Sci. 2007, 52(Suppl. (1)):204-206.
35. Sudha K., Rao A.V., Rao A. Oxidative stress and antioxidants in epilepsy. Clin. Chim. Acta 2001, 303(1-2):19-24.
36. Surazynski A., Miltyk W., Czarnomysy R., Grabowska J., Palka J. Hyaluronic acid abrogates nitric oxide-dependent stimulation of collagen degradation in cultured human chondrocytes. Pharmacol. Res. 2009, 60(1):46-49.
37. Svineng G., Ravuri C., Rikardsen O., Huseby N.E., Winberg J.O. The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. Connect. Tissue Res. 2008, 49(3):197-202.
38. Szklarczyk A., Lapinska J., Rylski M., McKay R.D., Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 2002, 22(3):920-930.
39. Ukeda H., Maeda S., Ishii T., Sawamura M. Spectrophotometric assay for superoxide dismutase based on tetrazolium salt 3'-1-(phenylamino)-carbonyl-3,4-tetrazolium- bis(4-methoxy-6-nitro) benzenesulfonic acid hydrate reduction by xanthine-xanthine oxidase. Anal. Biochem. 1997, 251(2):206-209.
40. Waldbaum S., Patel M. Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy?. J. Bioenerg. Biomembr. 2010, 42(6):449-455.
41. Wilczynski G.M., Konopacki F.A., Wilczek E., Lasiecka Z., Gorlewicz A., Michaluk P., Malinowska M., Okulski P., Kolodziej L.R., Konopka W., Duniec K., Mioduszewska B., Nikolaev E., Walczak A., Owczarek D., Gorecki D.C., Zuschratter W., Ottersen O.P., Kaczmarek L. Important role of matrix metalloproteinase 9 in epileptogenesis. J. Cell. Biol. 2008, 180(5):1021-1035.
42. Wu L.M., Fan L., Chen L.L. Precondition with doxycycline administration abates ischemia/reperfusion injury and reduces the expression of matrix metalloproteinase-1/9 in myocardium in rat in vivo. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007, 19(11):679-682.
43. Yeh D.Y., Lin H.I., Feng N.H., Chen C.F., Wang D., Wang N.T. Matrix metalloprotease expressions in both reperfusion lung injury and oleic acid lung injury models and the protective effects of ilomastat. Transplant. Proc. 2009, 41:1508-1511.